Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOPHIA: margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in previously treated HER2-positive metastatic breast cancer
NL-OMON47874Phase 3Active, not recruiting
- Sponsor
- MacroGenics
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of margetuximab in breast cancer (2 arms), sponsored by MacroGenics. Primary endpoints: Progression-free survival and Overall survival. Started Aug 2015; status: active, not recruiting.
02
Drugs
margetuximab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON47874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47874.